Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in End Stage Renal Disease on Peritoneal Dialysis
NCT05671991Phase 4Active, not recruiting
- Sponsor
- Yale University
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in end stage renal disease (ESRD), sponsored by Yale University. Primary endpoint: Glucose absorption. Started Mar 2023; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05671991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671991.